key: cord-0916235-xsutuwn0 authors: Chodick, Gabriel; Nutman, Amir; Yiekutiel, Naama; Shalev, Varda title: Angiotension-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection date: 2020-05-14 journal: J Travel Med DOI: 10.1093/jtm/taaa069 sha: f1cafd460ff971ccbdf9013a393fb2f252f7b939 doc_id: 916235 cord_uid: xsutuwn0 In a large Israeli dataset of 14 520 individuals tested for SARS-CoV-2, angiotension-converting enzyme inhibitors and angiotensin-receptor blockers were not found to be associated with increased SARS-CoV-2 infection after adjusting for major confounders. Patients on these medications should not stop their medication prophylactically. Highlight In a large Israeli dataset of 14,520 individuals tested for SARS-CoV-2, angiotensionconverting enzyme inhibitors and angiotensin-receptor blockers were not found to be associated with increased SARS-CoV-2 infection after adjusting for major confounders. Patients on these medications should not stop their medication prophylactically. Multivariable logistic regression model was used to assess the independent adjusted relationship between history of dispensed medication and SARS-COV-2 positivity with The results of this report suggest that the increased use of RAS-inhibitors among COVID-19 patients is fully explained by older age, male sex and higher prevalence of comorbid conditions including hypertension, diabetes, heart failure, and chronic kidney disease. We also have found no indication of reduced likelihood of infection among patients who were treated with CCBs that do not affect RAS. Curiously, in our cohort, heart failure had a protective effect. The observed reduced likelihood of infection found in our study may be due to detection bias, as shortness of breath is a common symptom of heart failure, which may have prompted testing in this population without other evidence of infection. Vitamin D has been suggested as a potential protective factor against COVID-19 infection by lowering viral replication rates and reducing concentrations of pro-inflammatory cytokines that injure the lining of the lungs, Our results show no association 7 between vitamin D levels and higher risk of COVID-19 infection. Several mechanisms have been suggested to explain the greater risk for COVID-19 among patients with diabetes and obesity. These include higher affinity cellular binding and a more efficient host viral entry, diminished viral clearance, reduced T cell function, and a greater susceptibility to hyper-inflammation and cytokine storm due to the infection 8 . They may also have a greater prevalence of underlying diseases that increase the risk of COVID-19 such as cardiovascular disease. In addition, these patients are more likely to develop severe COVID-19 symptoms and consequently to seek testing. In conclusion, we found that patients with co-morbid medical conditions, predominantly diabetes are at increased risk for COVID-19. Our data support current recommendations 9, 10 that patients on ACEIs or ARBs should not stop their medication prophylactically. Further research is needed regarding outcome of COVID-19 patients treated with these drugs. World Health Organozation. Coronavirus disease (COVID-19) Pandemic Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19 Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19 Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation and Cytokine Amplification in COVID-19 Renin-Angiotensin System Blockers and the COVID-19 Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 The authors have nothing to declare The authors have no conflict of interests Author contribution GC and VS were responsible for the study conception. GC and AN drafted the manuscript.NY was responsible for data collection and analysis. All authors contributed to interpretation of results.